Clinical Trial Update: A Dose Ranging Study to Evaluate the Safety and Potential Efficacy of rhNGF in Patients With Retinitis Pigmentosa (RP) [Phase 1, Phase 2]

View source ↗

Summary

A dose-ranging study of rhNGF in retinitis pigmentosa completed phase 1/2 with posted results in 2019.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Retinitis Pigmentosa

Drugs mentioned

• rhNGF (recombinant human nerve growth factor)

Snippet

Sponsor: Dompé Farmaceutici S.p.A | Conditions: Retinitis Pigmentosa | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2019-07-11